Clinical Trials Logo
  1. Home
  2. Non-small Cell Carcinoma
  3. NCT04171492

Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules — ALTITUDE  

Non-small Cell Carcinoma Clinical Trial

Official title:
A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules

Clinical Trial Summary

This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.

Clinical Trial Description

A multicenter, randomized controlled study with a blinded control arm. Open label arm is observational for lung nodule management. The clinical trial will evaluate the clinical utility of the Nodify XL2 integrated classifier when used in the clinical management of newly identified solid lung nodules assessed as < 50% risk of cancer by Mayo risk prediction algorithm. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04171492
Study type Observational
Source Biodesix, Inc.
Contact Niki Givens
Phone 7204951583
Email niki.givens@biodesix.com
Status Recruiting
Phase
Start date December 18, 2020
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03991819 - Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Withdrawn NCT05007769 - Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC Phase 2
Recruiting NCT05569291 - Investigating the Feasibility of a Physical Activity (Tele)Coaching Intervention in Patients With Non-small Cell Lung Cancer: an Explorative Study N/A
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Completed NCT00073398 - Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT05973487 - A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Phase 1
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05319886 - Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients
Active, not recruiting NCT04364048 - Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05551117 - A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors Phase 2
Completed NCT03394105 - Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer Phase 2
Not yet recruiting NCT04695925 - Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations Phase 3
Recruiting NCT06057766 - Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer N/A
Terminated NCT02376699 - Safety Study of SEA-CD40 in Cancer Patients Phase 1
Recruiting NCT05657873 - A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT05752552 - Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours Phase 1
Active, not recruiting NCT04791839 - Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer Phase 2